{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:04:35Z","timestamp":1777615475351,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ahj.2011.03.032","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T21:24:01Z","timestamp":1308950641000},"page":"106-114.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial"],"prefix":"10.1016","volume":"162","clinical-trial-number":[{"clinical-trial-number":"nct00239681","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michelle A.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco A.H.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto J.","family":"Lorenzatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith C.","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean G.","family":"MacFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2011.03.032_bb0005","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.03.032_bb0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"NEJM"},{"key":"10.1016\/j.ahj.2011.03.032_bb0015","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2011.03.032_bb0020","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.ahj.2011.03.032_bb0025","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.ahj.2011.03.032_bb0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0035","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.amjcard.2004.01.067","article-title":"C-reactive protein levels among women of various ethnic groups living in the United States (from the women's health study)","volume":"93","author":"Albert","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/HYPERTENSIONAHA.108.120584","volume":"53","author":"Kushiro","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.03.032_bb0045","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2011.03.032_bb0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.108.191259","article-title":"Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.03.032_bb0055","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0002-9149(99)80735-8","article-title":"Racial differences in coronary calcium prevalence among high-risk adults","volume":"75","author":"Tang","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.105.580696","article-title":"Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"113","author":"McClelland","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.03.032_bb0065","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/STROKEAHA.107.501700","article-title":"Effect of pretreatment with statins on ischemic stroke outcomes","volume":"39","author":"Reeves","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2011.03.032_bb0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1525-1497.2006.00349.x","article-title":"Ethnic differences in achievement of cholesterol treatment goals. Results from the national cholesterol education program evaluation project utilizing novel E-technology II","volume":"21","author":"Clark","year":"2006","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ahj.2011.03.032_bb0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ahj.2006.02.036","article-title":"Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy","volume":"152","author":"Yood","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.03.032_bb0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-American and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0085","first-page":"96","article-title":"Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six week trial","volume":"10","author":"Ferdinand","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0090","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2006.04.014","article-title":"Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial)","volume":"98","author":"Lloret","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0095","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.03.032_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/pgs.09.160","article-title":"Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins","volume":"11","author":"Chien","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ahj.2011.03.032_bb0105","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","article-title":"Effect of drug transporter genotypes on pravastatin disposition in European and African-American participants","volume":"17","author":"Ho","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ahj.2011.03.032_bb0110","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2005.04.051","article-title":"Race and gender differences in C-reactive protein levels","volume":"46","author":"Khera","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2005.01.039","article-title":"The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease","volume":"45","author":"Hu","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.03.032_bb0120","first-page":"565","article-title":"The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from NHANES-II mortality follow-up","volume":"100","author":"Martins","year":"2008","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.ahj.2011.03.032_bb0125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"373","author":"Sattar","year":"2010","journal-title":"Lancet"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:45:36Z","timestamp":1757569536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0002870311002626"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2011.03.032","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2011.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}